A second late-stage trial for the drug Simufilam has also been discontinued. Cassava Sciences (SAVA) shares are plunging in premarket trading and are losing most of their value after the biotech ...

Cassava is advancing simufilam through a pivotal ... use in patients with mild cognitive impairment or the mild dementia stage of Alzheimer’s. The two treatments are part of an early wave ...